PanTracer Portfolio

Now including PanTracer Pro

The PanTracer portfolio reflects our commitment to evolving with the needs of oncology care—offering tests that are practical, powerful, and designed to support real-world clinical decisions.

Product brochure

PanTracer Pro cancer types

PanTracer Portfolio

Guideline-driven tests for comprehensive genomic insights

The PanTracer portfolio empowers oncologists with actionable genomic insights for confident, real-time treatment decisions. Whether you’re selecting approved targeted therapies or exploring clinical trials, working from a liquid or tissue biopsy, PanTracer ensures that you’re equipped with the insights you need.

Our test portfolio includes liquid and tissue testing for patients with advanced-stage solid tumors, offering flexible ordering options designed to maximize genomic insights. Order tests independently or as complementary tests based on your patient’s unique needs. When every answer counts, PanTracer is there to support you.

PanTracer Portfolio

Video ID

fqw6idydmu

Player color

a9cf38

CSS ID

pantracer-video

CSS Classes

narrow

Precision oncology: Liquid and tissue CGP testing solutions for oncologists

Tissue Testing

Number of columns

Liquid Testing

Number of columns

PT Pro

NEO | PanTracer Pro

Test code

NTG-PTPO-03AX

Subtitle

One order to gain comprehensive insights for therapy selection

Simplifies case management and enables a path to personalized treatment, providing comprehensive insights in a single order.

Title color

Blue

Text fields

517-gene pan-solid
tumor NGS panel

Detects: SNVs, InDels, CNVs, RNA fusions, splice variants Includes MSI and TMB
(DNA/RNA NGS)

HRD assessment included

Homologous recombination deficiency (HRD) status for ovarian tumors

IHC and Ancillary Testing cancer type-directed

PT Tissue

NEO | PanTracer Tissue

Test code

NTG-PTTT-03AX

Subtitle

Comprehensive tissue profiling

Broad tissue-based CGP covering 517 genes with DNA + RNA sequencing for optimized fusion detection. Aligns with clinical guidelines and requires minimal tissue, enabling personalized therapy selection and trial matching.

Title color

Blue

Text fields

517-gene pan-solid
tumor NGS panel

Detects: SNVs, InDels, CNVs, RNA fusions, splice variants
Includes MSI and TMB
(DNA/RNA NGS)

No HRD analysis

PT Tissue HRD

NEO | PanTracer Tissue + HRD

Test code

NTG-PTTH-03AX

Subtitle

Comprehensive tissue profiling + HRD

Comprehensive tissue-based CGP with integrated HRD scoring (BRCA1/2 + GIS: LOH, TAI, LST) to guide personalized therapy—supporting precision care across the ovarian cancer continuum.

Title color

Blue

Text fields

517-gene pan-solid
tumor NGS panel

Detects: SNVs, InDels, CNVs, RNA fusions, splice variants Includes MSI and TMB
(DNA/RNA NGS)

HRD assessment included

Homologous recombination deficiency (HRD) status for ovarian tumors

PT LBx

NEO | PanTracer LBx

Test code

NTG-PTLB-02SX

Subtitle

Pan-solid tumor liquid biopsy genomic profiling

Liquid biopsy CGP analyzing 514 genes from a simple blood draw. Provides high-sensitivity ctDNA insights for real-time decisions when tissue is limited, inadequate, or not feasible.

Title color

Green

Text fields

514-gene liquid biopsy
NGS panel

Detects: SNVs, InDels, CNVs, Fusions (ctDNA-based only; no RNA sequencing)

No HRD analysis

PanTracer portfolio features

	Broad, guideline-compliant CGP panels Detection of alterations in over 500 cancer-related genes including SNVs, InDels, CNVs, fusions, MSI, TMB, and HRD status*.
	Rapid turnaround time to support timely decision-making Results in 8-10 days for tissue testing, and within 7 days for PanTracer LBx.
	Actionable and informative reports Clear, concise reports to support rapid clinical decisions. Including relevant therapy implications and clinical trial options.
	Flexible ordering options to ensure availability of biomarker results Our flexible ordering options support independent tissue or liquid testing, concurrent ordering for NSCLC, or liquid testing as a reflex if tissue testing fails.

*HRD scoring is validated for primary epithelial ovarian tumors

PanTracer Portfolio

Guideline-driven tests for comprehensive genomic insights

PanTracer Portfolio

Precision oncology: Liquid and tissue CGP testing solutions for oncologists

PT Pro

517-gene pan-solid tumor NGS panel

HRD assessment included

IHC and Ancillary Testing cancer type-directed

PT Tissue

517-gene pan-solidtumor NGS panel

No HRD analysis

PT Tissue HRD

517-gene pan-solid tumor NGS panel

HRD assessment included

PT LBx

514-gene liquid biopsy NGS panel

No HRD analysis

PanTracer portfolio features

Broad, guideline-compliant CGP panelsDetection of alterations in over 500 cancer-related genes including SNVs, InDels, CNVs, fusions, MSI, TMB, and HRD status*.

Rapid turnaround time to support timely decision-making​Results in 8-10 days for tissue testing, and within 7 days for PanTracer LBx.

Actionable and informative reports​​Clear, concise reports to support rapid clinical decisions. Including relevant therapy implications and clinical trial options.

Flexible ordering options to ensure availability of biomarker results​Our flexible ordering options support independent tissue or liquid testing, concurrent ordering for NSCLC, or liquid testing as a reflex if tissue testing fails.

517-gene pan-solid
tumor NGS panel

517-gene pan-solid
tumor NGS panel

517-gene pan-solid
tumor NGS panel

514-gene liquid biopsy
NGS panel

Broad, guideline-compliant CGP panels
Detection of alterations in over 500 cancer-related genes including SNVs, InDels, CNVs, fusions, MSI, TMB, and HRD status*.

Rapid turnaround time to support timely decision-making
Results in 8-10 days for tissue testing, and within 7 days for PanTracer LBx.

Actionable and informative reports
Clear, concise reports to support rapid clinical decisions. Including relevant therapy implications and clinical trial options.

Flexible ordering options to ensure availability of biomarker results
Our flexible ordering options support independent tissue or liquid testing, concurrent ordering for NSCLC, or liquid testing as a reflex if tissue testing fails.